🔴 Precigen is trading 20.17% down in pre-market after FDA's accelerated approval of rival RRP treatment

Precigen is trading 20.17% down in pre-market at $5.54 after a report linked the competitor’s FDA approval to its after-hours selloff. - The FDA granted accelerated approval to Inovio’s competing RRP treatment, Voceryq, on October 30. - Precigen’s RRP treatment, Papzimeos, is already on the market. - Precigen’s next scheduled quarterly results and business update are November 4; no new Precigen announcement for November 2 was identified.